Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Prostatype Genomics presents Quarterly- & Year End Report

Prostatype Genomics AB has today published its quarterly report for the fourth quarter comprising the period from 1 October 2021 to 31 December 2021, and the year end report for the financial year 2021. The report is available on the company website.Quarter 4 (1 October – 31 December 2021) summarized · Net sales amounted to 0 (347) TSEK. · EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -5 712 (-4 731) TSEK. · Cash flow from current operations in the quarter amounted -5 381 (-3 919) TSEK. · Total cash flow for the period amounted to -6 216 (

Platzer’s Annual Report 2021

Platzer’s Annual Report in Swedish is now published. The English version will be available on our website on March 21, 2022. The Annual General Meeting of Platzer Fastigheter Holding AB (publ) will take place on Wednesday, March 23, 2022. Platzer Fastigheter Holding AB (publ) For further information please contact:P-G Persson, CEO, Platzer, tel:  +46(0)734-11 12 22Fredrik Sjudin, CFO, Platzer, tel: +46(0)721-27 77 78 This information is information that Platzer Fastigheter Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was

Isofol Medical AB (publ) publishes year-end report, January - December 2021

GOTHENBURG, Sweden, February 24, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January – December 2021 is now available on the company's website, www.isofolmedical.com .Fourth quarter, October –December 2021 · Net revenue amounted to TSEK 4,704 (18,680) and other revenue to TSEK 0 (18) · The result for the period amounted to TSEK -61,170 (-54,659) · Earnings per share amounted to SEK -0.38 (-0.66) · Cash and cash equivalents on December 31 amounted to

The exercise period for warrants of series TO 1 begins today

Today, 24 February 2022, the exercise period begins for the warrants of series TO 1 that were issued in connection with Polymer Factory Sweden AB's (“Polymer Factory” or “the Company”) issue of units in April 2021. The exercise period lasts until March 17, 2022. Upon full exercise of warrants, the Company can receive a maximum of approximately SEK 5.2 million before issue costs.Information about warrants of series TO 1 In April 2021, Polymer Factory carried out an issue of units (shares and attached free of charge warrants) prior to listing on the Spotlight Stock Market. The issue of

Devyser Diagnostics AB publishes Year End Report for the period January to December 2021

Another record quarter "Devyser’s sales were also strong in the fourth quarter 2021, as well as in the other quarters of the year. We have continued to feel the impact of the pandemic, however, with new lockdowns in some countries during the quarter, particularly in Asia. We are therefore pleased to have maintained a good level of growth despite this. In the fourth quarter of the year, sales grew by 38 percent compared with the same period last year. Adjusted for exchange rate fluctuations, net sales increased by 40 percent.” Fredrik Alpsten, CEO Fourth quarter, October to December

Polygiene AB (publ.) Year-end report 2021

New financial targets and acquisitions process close out the yearQ4 in brief (October - December 2021) · Net sales amounted to MSEK 40.2 (26.6), a positive growth by 51 % · The operating profit/loss EBIT amounted to MSEK 3.9 (-2.4), an increase by 263 % · The gross margin amounted to 67.8 (64.9) % · The cash flow amounted to MSEK 2.7 (-3.1) Events during the quarter (October - December 2021) · Tricorp, leading workwear brand in the Netherlands launches products treated with Polygiene®, in which pre- and post-consumer waste is used · The reference Brazilian surf wear

Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List

· ZUBSOLV® will be available to all patients with Medicaid insurance in NY state effective March 22, 2022 · ZUBSOLV® market access improves in the public segment to 48 percent unrestricted access from 42 percent currently · ZUBSOLV® maintains unrestricted access to over 98 percent of patients in commercial segment Uppsala, Sweden – February 24, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence. This news follows the publication

Notice to the Annual General Meeting of Nordea Bank Abp

Nordea Bank AbpStock exchange release – Notice to general meeting24 February 2022 at 09.00 EET The shareholders of Nordea Bank Abp (the “Company”) are hereby summoned to the Annual General Meeting to be held on Thursday 24 March 2022 at 14.00 EET at the headquarters of Nordea, Hamnbanegatan 5, Helsinki, Finland. Shareholders and their proxy representatives can only participate in the Annual General Meeting and exercise shareholders’ rights by voting in advance and by making counterproposals and asking questions in advance. Instructions to shareholders are further described in Section

Nightingale Health Group’s Half-year report 1 July 2021 – 31 December 2021: Progressing faster than expected in line with strategy

Nightingale Health Plc Half-year report 1 July 2021 – 31 December 2021 (unaudited) Nightingale Health Group’s Half-year report: Progressing faster than expected in line with strategy Company Release, 24 February 2022 at 9:00 a.m. (EET) This release is a summary of Nightingale Health Plc's Half-year report from period 1 July 2021 – 31 December 2021. The full Half-year report is attached to this release. Numbers presented in brackets refer to corresponding year-on-year period unless otherwise stated. July–December 2021 key financials · Revenue was EUR 1.32 (1.01) million

Betolar and Belgian Tubobel sign a commercial agreement for a cement alternative Geoprime®

Betolar PlcCompany Announcement, inside information24 February 2022 at 8:47 A.M. EET Betolar and Belgian Tubobel sign a commercial agreement for a cement alternative Geoprime® Betolar Plc and the Belgian concrete company Tubobel Group enter into a commercial partnership to start production of low-carbon concrete products. The agreement with Betolar is valid until 2030. Tubobel, which manufactures concrete products for industry and road construction, starts manufacturing concrete pipes with Betolar's Geoprime® concept. Tubobel is the market leader in the manufacture of sewer pipes

Spinnova Plc’s Financial Statements Bulletin January–December 2021: Scaling accelerates and first technology sales materialise

SPINNOVA PLCCOMPANY RELEASE24 FEBRUARY, 2022 AT 8.45 A.M. EETSpinnova Plc’s Financial Statements Bulletin January–December 2021: Scaling accelerates and first technology sales materialise This release is a summary of Spinnova’s Financial Statements Bulletin for January to December 2021. The complete report is attached to this release and also available on the company’s website at https://spinnovagroup.com/reports/.January to December 2021 (Audited) · Revenue grew to EUR 6 063 thousand (EUR 254 thousand). · Operating loss for the period was EUR 7 172 thousand (EUR 5 473

Year-end Report January – December 2021

In 2021, we completed over 1,000 new residential units, started production on just over 1,600 units and added just over 3,600 units to our building rights portfolio, which at the end of the year amounted to just over 20,000 building rights. By the end of 2026, the number of completed properties for self-management must be over 6,000 completed units.January – December 2021 •  Net sales amounted to SEK 1,268 m (2,358). •  The operating profit was SEK 260 m (906), of which SEK 128 m (336) refers to changes in the value of investment properties. •  The net profit before tax for the

STILRIDE reaches new milestone with 100,000 sign ups for SUS1

The Swedish technology and design company STILRIDE was founded in 2020 with the ambition of taking a leading position within the rapidly growing area of electric motorcycles. Over the past two months, the company has closed an investment round, taken place in ABB's growth hub SynerLeap and attracted a lot of media attention around the world, including the UK, USA and Japan. They have also passed a milestone with over 100,000 potential customers signing up for interest in buying the SUS1.A year ago, the first concept pictures of STILRIDE's Sport Utility Scooter, SUS1, were published, and

Hunter Group ASA - Fourth quarter results 2021

Financial highlights Total revenues of USD 9.12m − Spot pool revenues of USD 1.69m − Time charter revenues of USD 7.01m Total operating expenses of USD 6.82m − Vessel opex incl. insurance of USD 2.33m − Voyage exp. and commissions of USD 0.56m − G&A expenses of 0.68m        - USD 0.29m administrative expenses        - USD 0.10m legal expenses        - USD 0.29m non-cash expenses EBITDA of USD 5.55m Net profit of USD 0.52m Average daily earnings of USD 24,100 − Avg. daily spot earnings of USD 18,400 −Avg. daily time charter earnings of USD 26,100

Interim report, May–January 2021/22

Strong demand, and supply chain challenges The demand for Elekta’s solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta’s strongest order backlog ever. However, the global supply chain challenges remained, and revenue and margins came in lower than last year. We are fully committed to returning to revenue growth and margin expansion. Gustaf SalfordPresident and CEO  Third quarter · Gross order intake amounted to SEK 4,441 M (3,954), corresponding to an 8 percent increase in constant currency.

Year-end report 2021 with interim report Q4

October - December 2021 Net sales increased by 23% Y-O-Y. Consolidated net sales ended at 57,404 (SEK 000s). EBITDA totaled -12,343 (SEK 000s). Operating profit, EBIT, was -30,786 (SEK 000s). Profit after tax was -26,887 (SEK 000s). Earnings per share was SEK -0.4. January - December 2021 Net sales increased by 25% Y-O-Y. Consolidated net sales ended at 210,826 (SEK 000s). EBITDA totaled -18,010 (SEK 000s). Operating profit, EBIT, was -69,864 (SEK 000s). Profit after tax was -87,141 (SEK 000s). Earnings per share was SEK -1.28.CEO's comments Growth journey back on track;

Notice to attend the Annual General Meeting of Skanska AB (publ)

Shareholders in Skanska AB (publ), Reg. No 556000-4615 (the “Company”), are hereby given notice of the Annual General Meeting (the “Meeting”) on Tuesday March 29, 2022.In light of the risk of the spread of Covid-19, the Board of Directors (the “Board”) has decided that the Meeting, pursuant to temporary legislation, will be conducted without physical presence, by shareholders exercising their voting rights only by postal voting.   Presentations by the Chairman of the Board, Hans Biörck, and the CEO, Anders Danielsson, where they among other things address some of the shareholders’

Nagarro swells to 15,000 colleagues worldwide

February 22, 2022: Nagarro, a global leader in digital engineering, announced that the size of the Nagarrian family had crossed the 15,000 mark. Even in a highly competitive job market, Nagarro continues to attract great engineering talent on the strength of its interesting digital projects and its unique culture. Meanwhile, Nagarro also continues to attract entrepreneurs looking for a good home for their companies and a larger playing field for themselves.   Paul Haberfellner, a Co-founder, said: "My stream of Nagarro started with only a handful of people! The other streams of

Key information relating to the cash distribution to be paid by MPC Container Ships ASA

Oslo, 24 February 2022 The distribution will be made from previously paid in share premium transferred from the Company's share premium account. Distribution amount: USD 0.11 per share Declared currency: USD. Payment to shares registered with Euronext VPS will be distributed in NOK. Last day including right: 23 March 2022 Ex-date: 24 March 2022 Record date: 25 March 2022 Payment date: 30 March 2022 (on or about) Date of board resolution: 23 February 2022 This information is published in accordance with the requirements of the Continuing Obligations. For further

MPC Container Ships ASA reports Q4 and twelve-month 2021 results

· Significantly improved operating revenues of USD 142.5 million and EBITDA of USD 162.7 million, up by 20% and 121%, respectively, compared to Q3 2021. · Quarterly dividend of USD 0.11 per share (around USD 50m) declared for Q4 2021. · Projected EBITDA backlog now in excess of USD 1.1 billion · The FY 2022 EBITDA guidance in the range of USD 450-470 million. Oslo, 24 February 2022 Q4 and twelve-month 2021 results: MPC Container Ships ASA ("MPCC" or the "Company", together with its subsidiaries the "Group") today published its unaudited financial report for the twelve-

Year-end report October - December 2021

Curasight A/S (“Curasight” or “the Company”) hereby publishes the Year-end report for the period October 1 – December 31, 2021. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “As we close the books for the financial year 2021, we can look back on an eventful year in Curasight’s history. In 2021 we have accomplished several important milestones including strengthening Curasight’s IP position within diagnostics and therapy with patent approvals in both US and

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during eighth exercise period

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or “the company”) today announces that the eighth period to subscribe for shares in the company by exercise of warrants (ticker CTM TO1) (“the warrants”) commences today, 24 February 2022, and will run until and including 5 March 2022. During this period, each warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 18.90. Payment of subscribed shares can be made in cash or through set-off with the full nominal amount of each hybrid capital security (ticker

Year-End Report, 2021

Calliditas became the first Company to receive accelerated approval in IgA Nephropathy.“The accelerated approval of TARPEYO was for the indication of reduction of proteinuria, which was the endpoint of Part A of the trial, in adult patients with IgA nephropathy with risk of rapid progression, which is characterized as generally UPCR ≥ 1.5 g/g.  It is well established that patients with higher levels of proteinuria have a worse outlook and prognosis as they tend to experience a more rapid decline of their kidney function, as measured by eGFR. These patients are therefore at considerable risk

BEWI – Results for the fourth quarter of 2021

BEWI, a leading provider of packaging, components, and insulation solutions, today reported its results for the fourth quarter of 2021. BEWI recorded net sales of 208.2 million euro for the fourth quarter of 2021, compared to 130.2 million euro for the same quarter last year, corresponding to an increase of 60 per cent, of which 43 percentage points are organic growth driven by higher volumes and sales prices following strong demand. Adjusted EBITDA came in at 26.4 million euro for the quarter, up from EUR 16.4 million for the fourth quarter last year. The company’s upstream segment, RAW,

There are no items matching the current filter
There are no more items matching the current filter
Back to top